Mutant KRAS at the heart of tumor immune evasion


In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.

Journal details

Journal Immunity
Volume 52
Issue number 1
Pages 14-16
Publication date